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The mission of the Forschungszentrum Dresden-Rossendorf (FZD) is excellence in long-term
research in socially important issues like energy, health, and advanced material technologies. In
strategic collaborations with partners from research and industry the FZD contributes to solve major
challenges of modern society. Scientific work at the research center focuses on three questions:
◆ How does matter behave in strong fields and at small dimensions?
◆ How can cancerous tumors be identified in the early stages and treated effectively?
◆ How can the public and the environment be protected from technical risks?
Corresponding to these questions, the Forschungszentrum Dresden-Rossendorf pursues the 
three program topics “Advanced Materials Research”, “Cancer Research”, and “Nuclear Safety
Research”. This Biennial Scientific Report highlights the scientific achievements of the “Cancer
Research” program, covering the years 2007 and 2008. The first part introduces the overall focus 
of the program as well as the large-scale facilities that are used for research, and the second part
consists of eight articles on research projects that were conducted by scientists of the following
institutes and common projects:
◆ Institute of Radiopharmacy
◆ Institute of Radiation Physics
◆ OncoRay – Center for Radiation Research in Oncology
◆ Network project onCOOPtics 
In 2007, the FZD was evaluated by the German Council of Science and Humanities (Wissenschafts-
rat). In its final evaluation report, published in July 2008, the Council unanimously recommended
that the FZD – a Leibniz institution – should become a member of the Helmholtz Association. The
report emphasizes: “Since the last evaluation by the German Council of Science and Humanities, 
the FZD has continuously worked on long-term and highly complex research topics, thus expanding
its scientific profile towards a major research center. This top-level research on a strategic and long-
term basis in politically and socially important issues suggests an increased financial commitment of
the Federal Republic of Germany.”
To highlight a few noteworthy events in 2007 and 2008, one must mention the promising industrial
collaborations of the Institute of Radiopharmacy at the FZD. The expertise of its scientists in fun-
damental research in the fields of radiochemistry, radiopharmacy, biology, and physics established
the basis for joint research projects with, for example, GlaxoSmithKline (Great Britain), ROTOP
Pharmaka AG (Germany), and ABX Advanced Biomedical Compounds GmbH (Germany). This
report focuses on recent works on nanoparticles for cancer treatment (ROTOP) as well as multi-
modality imaging and patient-movement correction as powerful tools for approved cancer
diagnostics (ABX). 
Research on laser-particle acceleration is a newly established division of the Institute of Radiation
Physics, aiming at the development of compact laser-based accelerators for a novel approach in
cancer treatment. The 150 Terawatt laser source was inaugurated in spring 2008. The FZD is very
glad that it could attract Prof. Thomas E. Cowan as new director of the Institute of Radiation 
Physics as of February 2008. He is an accelerator and laser specialist with a strong interest in
medical applications. Consequently, he has been engaged in the newly established “Joint Center 
for Radiation Research in Oncology”, which significantly extends the collaboration between the
University Hospital Carl Gustav Carus, Technische Universität Dresden, and FZD. A central aspect 





and ions. A coordinated application for a Saxon State Excellence Initiative convinced the experts and
the Center was chosen as one of four Saxon excellence projects in August 2008. All these activities
follow the shared vision to further advance Dresden’s role as a leading location for cancer research
and cancer therapy.
Prof. Wolfgang Enghardt, a leading medical physicist in Dresden – he is professor at Technische
Universität Dresden, OncoRay, and FZD – was awarded the very prestigious IBA-Europhysics Prize
2007 for his successful research for the improvement of cancer therapy with ions. Together with 
Dr. Dieter Scharf from the GSI in Darmstadt, he contributed substantially to the German heavy ion
therapy project. While Dr. Scharf investigated the interaction of particles with human tissues, Prof.
Enghardt developed an advanced technology for the online-monitoring of particle therapy, known
as in-beam PET. Prof. Enghardt also supervised the research of Ph.D. student Dr. Fine Fiedler, who 
is now a scientist at the Institute of Radiation Physics and whose Dissertation work on in-beam PET
using helium ions was honored with the 2007 Christoph Schmelzer Award of the Society for the
Promotion of Tumor Therapy with Heavy Ions.
To strengthen the international visibility of the FZD in the scientific community, the FZD served 
as the local organizer of the IEEE Meetings “Medical Imaging Conference (MIC)” and “Nuclear
Science Symposium (NSS)”.  The 2008 IEEE-NSS-MIC Conference took place in Dresden from
October 19 to 25, and scientists of the Cancer Research program were actively engaged in it. 
Under the direction of Prof. Wolfgang Enghardt, the “Medical Imaging Conference 2008” 
focused on oncology. This provided the unique opportunity for Dresden scientists involved in 
cancer research to present their latest results. In addition, Prof. Jörg van den Hoff, head of the FZD
PET Center, organized a special IEEE-NSS-MIC short course on PET pharmacokinetics, which was
attended mainly by young scientists. All in all, the IEEE Conference in Dresden attracted more than
2,700 participants, thus being the largest IEEE-NSS-MIC Conference ever. We are very grateful to
the German Science Foundation (DFG) and the Saxon State Ministry of Higher Education, Research
and the Arts (SMWK) for their essential contributions of funding for the Conference. 
The success of a research institution strongly depends on the motivation and dedication of talented
young scientists. The FZD has put a lot of effort into attracting junior scientists from Germany and
abroad. Our six institutes strive for excellent working conditions and support of their staff, the FZD
as a whole offers Ph.D. seminars to about 120 doctoral students, a tenure track program for out-
standing postdoctoral staff, special workshops for young scientists such as communication to the
media, presentation in English, training for young science managers, etc. The FZD supports high-
level training as well for its technical staff and its almost 60 trainees. In 2008, the FZD received the
“Audit Beruf und Familie” (Career and Family Certificate) from the Hertie Foundation, underlining
the particular importance attached to the healthy balance of family and career at the FZD.
Finally, this preface gives me the opportunity to thank our funding institutions, the Saxon State
Ministry of Higher Education, Research and the Arts (SMWK) and the Federal Ministry of Education
and Research (BMBF), for their continued support, our national and international scientific coop-
eration partners for many successful joint research endeavors, and the entire staff of the FZD for
their dedicated work. 
Prof. Dr. Roland Sauerbrey
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Jörg Steinbach, Thomas E. Cowan
The goal of the Cancer Research program
is to strengthen the fight against cancer -
together with partner institutions, primarily
in the Dresden area, within the framework
of the “OncoRay” collaboration. The
common basis of merging these efforts is
the utilization of ionizing radiation as one
of the principal techniques to destroy
tumor tissue, as well as its application for
diagnostic purposes. This program brings
together scientists from various research
fields such as radiopharmacy, biochemistry,
radiation physics, laser physics, radiation
oncology, nuclear medicine, and others. It
enables a translational research, from basic
natural sciences, by way of preclinical
research, up to the clinical application. Our
research thus intends to benefit society by
developing tools for earlier diagnosis and
improved treatment of tumors, which are
one of the most pervasive health problems
in the modern society.
This common challenge is undertaken 
at the FZD within the context of various
research groups, departments, institutes
and research plans. Radiopharmacists 
aim for the development and application
of radionuclide-labeled compounds 
for diagnostic and therapeutic purposes
directly at, or even within, the tumor 
cells, whereas physicists are pursuing the
development and control of new sources
for external irradiation of malignant tissue. 
The aim of the radiopharmaceutical tumor
research is to contribute to molecular
imaging and molecular therapy of tumors.
Radiopharmaceutical tools enable thera-
peutic interventions by radionuclide
therapy - ERT (endo radionuclide therapy)
as well as accompanying this by analytical
and diagnostic investigations utilizing
methods of Molecular Imaging as PET
(Positron Emission Tomography), first of all
utilizing newly developed radiotracers. Our
goals include understanding mechanisms
of tumor growth and development, the
search for new molecular targets, the
Cancer Research program 
at the Forschungszentrum Dresden-Rossendorf
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monitoring of the progress of tumor growth and its dependence on therapeutic
interventions such as internal and external irradiation, the follow up after treatment,
and consequently the development of new substances and principles for PET and ERT.
These efforts are based on organic positron-emitting radionuclides such as 18F, 11C, and
also on pairs of radiometals such as 86Y/90Y, 64Cu/67Cu, 99mTc/188Re, which enable
both diagnostics and therapy. The radiopharmaceutical research program involves the
projects “Translational tumor research”, “Radiotherapeutics” as well as “PET and
multimodal imaging”. The application of radiolabeled compounds on humans and
respective research programs are performed in the frame of the joint PET Center (FZD
and Clinic of Nuclear Medicine/Technische Universität Dresden), enabling direct
translational research based on current projects.
An important new research direction is the development of new particle accelerators,
based on high-intensity and high-power laser systems, for particle-beam therapy of
cancer. Laser-driven particle beams are accelerated to high energy over very short
distances (mm), therefore offering the future prospect of compact particle-therapy
machines which could fit in existing clinics. The temporal structure of the beams is
different than conventional accelerators, with much higher instantaneous dose rate in
fewer, very short pulses. An important step towards future medical application is to
evaluate the biological effectiveness of laser-accelerated particle beams, in comparison
to conventional radiotherapy. The world’s first systematic study of cell irradiation with
laser-accelerated electron beams has been carried out. The potential for laser-driven
particle therapy appears promising, and a great deal of research is focused on
developing laser-accelerated ions for the next step of this study, which will be to assess
the biological effectiveness of laser-accelerated protons and ions in cell irradiation. 
Important for both present particle-therapy treatment using accelerators, and potential
future application of laser-driven particle beams, is the improvement of characterization
of the radiation dose delivered to a patient. Particle beams for therapy offer the
advantage of depositing most of their dose at the end of the particle’s range (i.e. the
penetration depth in the patient). In comparison to conventional photon-radiation
therapy, it is therefore particularly important to characterize the particle penetration
and the delivered dose distribution, so as to best target the tumor while avoiding
healthy tissue. Positron emission tomography during the particle therapy has been
developed previously by FZD in collaboration with GSI Darmstadt as a useful technique
for monitoring the delivered dose by imaging the radioactive decay of positron-
emitting nuclei produced by activation along the beam path. In collaboration with
Siemens AG, different PET detector configurations were evaluated for optimizing the
quality of the PET imaging of the dose delivery. In further work led by the Medical
Radiation Physics group of OncoRay, PET was combined with Computed Tomography,
to further improve the dose localization by means of the complementary information
available from these two techniques, which for example allows to perform better
attenuation corrections to the PET imaging. Moreover, new techniques are developed
to correct for patient motion and organ movement, for example due to breathing,
which allow to target the tumor more precisely with the particle beam, in a technique
known as image-guided radiotherapy.
Within this context the Rossendorf research groups are involved in the common
program OncoRay and onCOOPtics together with the University Hospital “Carl Gustav
Carus” Dresden and the Technische Universität Dresden. In the continuing evolution in
these common research activities, these institutions are constructing a new, common
research unit, the “Gemeinsames Zentrum für Strahlenforschung in der Onkologie“
(Joint Center for Radiation Research in Oncology). This will provide the basis for trans-
ferring these results to translational research, that is, their application to humans, and
will enable us to utilize other newly established scientific infrastructures in the Dresden
area as the “Center for Regenerative Therapies Dresden” (CRTD).
High-intensity and high-power laser systems,
such as the 150 TW laser at the FZD, named
Draco, offer the future prospect of compact




OncoRay is a joint project focused on
radiation research in oncology and was
established in 2005. It is funded within a
program of the German Federal Ministry 
of Education and Research (BMBF) sup-
porting top-level research. OncoRay is
located at the Medical Faculty Carl 
Gustav Carus and jointly operated by 
the Technische Universität Dresden, the
University Hospital Carl Gustav Carus
Dresden, and the Forschungszentrum
Dresden-Rossendorf.
What does OncoRay stand for?
OncoRay’s vision is to improve the
treatment of cancer by means of bio-
logically individualized and technically
optimized radiotherapy. Radiotherapy has
proven itself as a highly effective method
of treating the primary tumor, which can
often be completely cured. In contrast to
other treatment modalities, radiotherapy
offers precise spatial distribution of the
treatment to individual patients. For these
reasons, a replacement is unlikely in the
foreseeable future. On the contrary, in 
the coming decades radiotherapy will be
revolutionized through the development 
of new high-precision delivery techniques
and the integration of new advances in
biology. This requires the careful inter-
weaving of multiple disciplines including
biology, physics, and medicine.
How is OncoRay organized?
OncoRay connects different research
groups which are aimed at the practical
need for preclinical and clinical trans-
lational research in radiation oncology, i.e.
the transfer of results from basic to applied
research for the benefit of the patient. 
Five newly established in-house groups
complement ten previously existing
research groups at the University Hospital
Carl Gustav Carus Dresden (radiotherapy,
experimental radiotherapy, radiobiology,
nuclear medicine, and radiology), at the
Forschungszentrum Dresden-Rossendorf
(radiation physics, laser particle acceler-
ation, and radiopharmacy), as well as at
the Technische Universität Dresden
(radiation physics, nuclear energy
technology). 
The five in-house groups deal with
interdependent fields of inquiry with a
particularly high promise for innovation.
They are aimed at the improvement of
radiotherapy following different strategies:
In order to treat cancer it is necessary to
understand the molecular mechanisms of
cancer cells, which is the aim of OncoRay’s
Biological and Molecular Targeting group.
Scientists here are particularly interested in
the role of cell-to-extracellular matrix
interactions for the resistance of tumor
cells to radiotherapy and chemotherapy.
The cell surface receptors facilitating the
interaction of tumor cells with the extra-
cellular matrix are called integrins and
occur more often than normal in various
malignant tumors such as squamous cell
carcinomas of the head and neck or
pancreatic ductal adenocarcinomas. 
A research assistant of the Biological and Molecular Targeting group is injecting DNA into an Agarose gel.
Agarose gel electrophoresis is a method to separate DNA or RNA molecules by size.
OncoRay – Radiation Research in Oncology
OncoRay is funded by the BMBF: 03ZIK041, 03ZIK042 & 03ZIK445
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The research group was for instance 
able to show that in newly established
three-dimensional cell culture models the
sensitivity of tumor cells to radiation is
significantly increased by the specific
inhibition of the integrin beta1. This could
also be confirmed in xenograft models 
in nude mice. During the analysis of the
molecular mechanisms leading to this
radiosensitization by beta1 integrin in-
hibition, further potent targets essentially
involved in tumor cell radiosensitivity 
were identified.
In order to improve radiation therapy
advanced diagnostic imaging aimed at a
highly individualized therapy is required,
which is in the focus of the Biological and
Molecular Imaging group. It is a platform
for research in the field of imaging, e.g. of
lung cancer and head and neck tumors,
using multimodal imaging with positron
emission tomography (PET), computed
tomography (CT), and magnetic resonance
imaging (MRI). PET utilizes for instance
intravenously injected radioactive sugar
(18F-fluorodeoxyglucose - FDG) in
homeopathic doses in order to visualize
tissues with a high glucose turnover. The
capabilities of the fusion of these comple-
mentary data provided by PET, MRI, and
CT are investigated in the preclinical and
clinical setting.
Radiation dose is a key for improving the
outcome of the therapy. In order to reduce
the dose to sensitive normal tissue without
compromising tumor coverage several
strategies are feasible. Traditional X-ray
computed tomography is for instance
combined with FDG PET/CT in order to
enhance the reliability of target volume
definition and, thus, to reduce safety
margins. The Medical Radiation Physics
research group (see article on page 26)
closely collaborates with Siemens Health
Care, implementing the whole chain from
diagnostic imaging to tumor conformal,
image guided dose delivery, in particular (i)
4D PET/CT imaging of targets influenced
by breathing motion, (ii) precise
attenuation correction and thereby
quantification for PET images of structures
influenced by the breathing motion, (iii)
tumor conformal treatment planning in
moving organs, and (iv) gated beam
delivery.
Tumor tissue is no homogenous mass 
of cells, which influences the efficacy of
therapy. Instead, human solid tumors and
their metastases are determined by various
characteristics such as tumor cell metab-
olism, local micromilieu, and stromal
cellular environment consisting of fibro-
blasts, endothelial, and immune cells. The
aim of the Tumor Pathophysiology group
is to gain insight into and interfere with
pathophysiological mechanisms leading to
tumor progression and therapeutic
resistance. 
Many tumors cannot be reached by state-
of-the-art radiotherapy technology, which
is based on photon or electron beams
delivered by compact electron linear
accelerators. The Laser-Radiooncology
group develops high-intensity lasers for
innovative radiation treatment using ions,
whose favourable physical and radio-
biological properties have already been
demonstrated in clinical application. The
Laser-Radiooncology research group is 
part of the BMBF funded joint project
onCOOPtics between the OncoRay center
in Dresden and the ultra optics center in
Jena (see article on page 24).
How does OncoRay support young
scientists?
OncoRay is strongly engaged in further
education and aims at decreasing the
severe shortage of experts in different
disciplines of Medical Radiation Sciences,
which we currently experience in all fields
of clinical radiology (medical radiation
physics, radiotherapy, nuclear medicine,
diagnostic radiology, radiology) in
Germany as well as in many European
countries. The OncoRay Postgraduate
School, founded in 2005, provides in-
depth postgraduate education for
physicists, engineers, biologists, and
medical doctors. The core of the
Postgraduate School is a four-semester
Master of Science Course (M.Sc. “Medical
Radiation Sciences”) combined with clinical
training of accredited medical physics
experts. In 2007, the first eight students
graduated from the program. All of them
received interesting job offers long before
the end of the program. In addition to the
MSc course, the School offers a PhD (or
MD) track for all students writing their
doctoral thesis at OncoRay. This program
offers obligatory courses such as bio-
statistics or the basic science of radiation 
as well as specific voluntary components.
➡ www.oncoray.de
Radiation therapy is one of the three columns of cancer treatment. Scientists at the Medical Radiation




The interaction of very high intensity laser
light with matter can produce intense
radiation pulses and beams of particles
accelerated to high energy over very short
distances (sub mm). The development of a
new ultrahigh intensity laser at the FZD has
enabled research towards the particularly
exciting prospect of using laser-accelerated
ions for cancer therapy. This research could
potentially lead to compact, hospital-scale
ion accelerators, which could significantly
extend the availability of ion beam tumor
therapy beyond the limited number of
patients that can presently be treated in
large-scale medical accelerator facilities.
The 150 TW laser system Draco (Dresden
laser acceleration source) represents a new
generation of chirped-pulse-amplification
Ti:Sapphire lasers, where pulse durations of
less than 30 fs can be obtained at a pulse
energy of several Joule, and with a pulse
repetition rate of 10 Hz. Active manage-
ment of the gain bandwidth, as well as
dedicated nonlinear pulse cleaning tech-
niques, allow for 100 TW class peak
powers on target at an unprecedented
pulse contrast of the order of 1010. 
Two different target areas will be operated,
one for ion acceleration and related cell
irradiation studies, and a second heavily
shielded one connected to a beamline of
the ELBE accelerator for laser-electron
acceleration and X-ray generation studies.
The ion target area was commissioned in
the second half of 2008, following the
construction of the laser lab and the
installation of the laser system inside the
ELBE building during the first half of 2008.
The laser beam has been focused, with a
short focal-length off-axis parabolic mirror,
to a small spot diameter of only 4.5 µm,
which has allowed to reach a focal
intensity of the order of 5x1020 W/cm2 
on target.
At such extremely high intensities, ions are
accelerated from the rear surface of laser-
irradiated thin foils. A first test with a
rather thick 13 µm aluminum foil, which
was used for commissioning the target
opto-mechanical and the ion detection
systems, led already to laser-accelerated
protons with energies of up to about
5 MeV, as shown in Fig. 1. 
The development of our laser and
experiment capabilities is accompanied and
complemented by sophisticated computer
simulations of the laser-target interaction
process. The close interplay of experiment,
theory, and simulation is essential for a
comprehensive understanding of the laser-
matter interaction and the development of
new targets for laser particle acceleration.
In collaboration with researchers from
Belfast, Munich, and the University of
Nevada (USA), two Particle-in-Cell
simulation codes have been installed and
are actively in use by our group. First
studies aim at improving the absorption
efficiency of the laser light in extremely
thin targets and specially-arranged stacks
of target foils, as well as by micro-
structuring of the target – an example 
is given in Fig. 2. 
Laser particle acceleration at the FZD: 
proton acceleration experiments launched
Facilities for Europe
Fig. 2: Particle-in-Cell computer simulation
showing the density of ions arising from the
expansion of an ultrathin solid foil (initial density
1.1x1022cm-3, equal to 10 times the critical
density nc ) about 700 fs after the interaction
with a 1020 W/cm2 30 fs laser pulse (incident
from the left). The pronounced 2D structures
arose from the interaction of protons with the
ponderomotive force of the laser as the target
became transparent during the interaction.
Fig. 1: First quasi-exponential
proton energy spectrum
generated by irradiating a 
13 µm Al foil at an intensity 
of 5x1020 W/cm2. The false
color plot illustrates the
intensity distribution of the
laser focal spot. 
Project partners
· Queen’s University, Northern Ireland
· Max-Planck-Institut für Quantenoptik, 
Germany
· University of Nevada, Reno, USA
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Jörg van den Hoff
The Positron Emission Tomography (PET)
Center is jointly operated by the FZD and
the Technische Universität Dresden. The
infrastructure comprises a dedicated
cyclotron, GMP (Good Manufacturing
Practice) approved radiopharmaceutical
laboratories, and several tomographs: 
a human PET tomograph and, for small
laboratory animals, dedicated tomographs
for PET, magnetic resonance imaging and
spectroscopy (7 Tesla MRI/MRS), and
computed tomography (CT).
As its central resource, the PET Center
provides molecular imaging capabilities 
for noninvasive in vivo investigation of
physiological and biochemical processes
related to different pathophysiological
states, notably in tumor diseases. The PET
technique is able to noninvasively deliver
quantitative information on cellular
transport processes and metabolism (tissue
perfusion, distribution volumes, turnover
rates, and so on) in an unparalleled way.
PET utilizes radioactive tracers at the nano-
and picomolar concentration level, thus
excluding any interference of the measure-
ment with the systemic metabolism. PET
accurately provides the three-dimensional
distribution of the tracer concentration
with a spatial resolution of better than
2 mm in the case of dedicated small animal
tomographs. Performing these measure-
ments allows assessing the time depend-
ence of the tracer distribution and, thus,
quantification of relevant pharmacological
parameters.
Research at the PET Center is focused on
investigations of transport, metabolism, 
and signal transduction in normal tissue 
as well as damaged and tumor tissues with
the PET method. Our multi-disciplinary
research group of radiochemists, bio-
chemists, biologists, physicists, software
engineers, and physicians addresses this
task by the development of new PET
tracers, biological characterization of their
properties, multi-modal imaging of small
animal tumor models with new and
established tracers, development of new
image data acquisition and evaluation
techniques, and, finally, clinical studies 
in humans.
An important part of this work is to
advance biologically individualized,
technically optimized radiotherapy, which
is also the main goal of the Center for
Radiation Research in Oncology
“OncoRay”. In this context, our efforts are
focused on the systematic evaluation of
various tracers for assessing tumor vitality
and radiation sensitivity and the sub-
sequent seamless integration of the
quantitative information derived from 
PET into radiation treatment planning 
and therapy response control. Secondly,
research at the PET Center focuses on the
investigation of pathomechanisms of
metabolic and inflammatory diseases such
as the metabolic syndrome. Apart from
these research projects, our imaging
techniques are also utilized in pre-phase I
clinical trials for drug development in
collaboration with the pharmaceutical
industry.
The PET Center
PhD student Katrin Müller in a radiopharmaceutical laboratory.
RESEARCH INSTITUTE OF RADIOPHARMACY
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Jens Pietzsch, Torsten Kniess, 
Ralf Bergmann
For more than a century, scientists have
suspected inflammation and cancer to be
intertwined, with the former somehow
provoking the latter (Fig. 1). Indeed,
several studies have suggested that about
15 % of malignancies worldwide are
attributed to inflammation (Table 1). But
how an inflammation inside an organ
triggers cancer has mostly remained a
mystery. The inflammatory microenviron-
ment, which is characterized by the
accumulation of different types of
inflammatory cells in the tissue stroma and
epithelium, may support the development
of malignancy by secreting various
proteases, mitogenic, antiapoptotic, and
angiogenic factors. Very recently, the
enzyme cyclooxygenase-2 (COX-2) has
been identified as one piece of the puzzle
(Fig. 2). Cyclooxygenases control the
complex conversion of twenty-carbon
polyunsaturated fatty acids, e.g. arachi-
donic acid, to oxygenated derivatives, 
such as prostaglandins, prostacyclins, 
and thromboxanes. These derivatives,
collectively termed eicosanoids, are
signaling molecules which trigger many
physiological and pathophysiological
responses. 
Cyclooxygenases exist in two distinct
isoforms, a constitutively expressed form
(COX-1) and an inducible form (COX-2).
COX-1 and COX-2 are very similar in their
structure and share the same substrates,
generate the same products, and catalyze
the same reactions using identical catalytic
mechanisms. The COX-1 enzyme is
expressed in resting cells of most tissues,
functions as a housekeeping enzyme, and
is responsible for maintaining the normal
metabolism of eicosanoids. COX-2 is
predominantly found in the brain and in
the kidneys while being virtually absent in
most other tissues. However, COX-2
expression is significantly up-regulated as
part of various acute and chronic inflam-
matory conditions. COX-2 expression 
can be induced in fibroblast, epithelial,
endothelial, macrophage, and smooth
muscle cells in response to physiological
and stress signals.
Not only is COX-2 associated with
inflammation and pain, but it is well
documented that especially COX-2 is 
Cyclooxygenase-2: 
a key player in inflammogenesis of cancer
Fig. 1: In 1863, German pathologist Rudolf Virchow (1821-1902) noted white blood cells, leucocytes, in
neoplastic tissues and drew a connection between inflammation and cancer. He first suggested that the
“lymphoreticular infiltrate” reflected the origin of cancer at sites of chronic inflammation. Picture: Rudolf
Virchow: Die krankhaften Geschwülste. Dreissig Vorlesungen, gehalten während des Wintersemesters 
1862-1863; with friendly permission by Sammlung Dr. Hans-Peter Haack, Leipzig.
Table 1 Varieties of cancer associated with inflammation
Cancer Inflammatory stimulus/condition 
Colorectal Inflammatory bowel disease 
Gastric Helicobacter pylori induced gastritis, MALT lymphoma 
Hepatocellular Chronic hepatitis, Hepatitis viruses
Pancreatic Chronic pancreatitis
Bladder Schistosomiasis, Bladder dysplasia 
Cervical Papillomaviruses, Cervical dysplasia 
Ovarian Pelvic inflammatory disease, Talc 
Esophageal Barrett’s esophagus (Barrett’s metaplasia)
Head/Neck Oral leukoplasia
Bronchial Silica, Asbestos, Cigarette smoke 
Mesothelioma Asbestos 
Prostate Prostatic intraepithelial neoplasia
Skin Actinic keratoses, Herpes viruses
Research
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over-expressed in many human cancer
entities. The COX-2 enzyme is assumed 
to play an important role in carcinogenesis
by stimulating cell proliferation, inhibiting
epithelial differentiation, enhancing cell
invasiveness and tumor metastasis,
inhibiting apoptosis, mediating immune
suppression, and increasing the production
of mutagens. COX-2 also stimulates
angiogenesis, a crucial process for tumor
growth and metastasis. Reciprocally, the
blockade of COX-2 mediated processes has
a strong potential for cancer prevention
and therapy. Accordingly, drugs targeting
cancer-related inflammatory processes have
the potential to re-educate a cancerogenic
inflammatory microenvironment into
becoming a cancerostatic microenviron-
ment. This potential to reverse cancer-
promoting inflammation could stimulate 
an exciting new field for anticancer
therapies. 
However, an essential prerequisite is 
the detailed understanding of the
(patho)physiological role of COX in vivo.
Currently, an accurate assessment of 
COX-2 expression levels and/or activity 
in organs or tissues can only be achieved
by laborious analyses ex vivo. Thus, the
development of selective probes for COX
subtypes and non-invasive monitoring of
COX functional expression by means of
nuclear molecular imaging techniques, 
like positron emission tomography (PET),
provide unique opportunities to obtain
data on COX expression levels during
disease progression and the potential 
role particularly of COX-2 in diseases.
Moreover, the development and in vivo
study of appropriately radiolabeled
compounds as selective COX-2 inhibitors
would provide pharmacological data 
which may help to understand their 
exact physiological actions and metabolic
pathways. In this regard, efforts have been
made to develop COX-2 selective inhibitors
for anti-inflammatory and cancer therapy
since the discovery of the COX-2 enzyme
in the early 1990s. Due to the structural
similarities of the COX-1 and COX-2
enzyme, the search for selective inhibitors
for COX-2 versus COX-1 has, however,
remained a formidable challenge. The
Institute of Radiopharmacy at the FZD is











Fig. 2: Inflammatory and cancerogenic pathways involving cyclooxygenase-2 mediated prostaglandin
synthesis and activation of tumor and inflammatory cells, respectively (according to [3]).
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In 1971, John R. Vane and colleagues
discovered that all effects of Aspirin arise
from its inhibition of the synthesis of
prostaglandins from arachidonic acid [1],
which earned the scientists the Nobel Prize
in Medicine in 1982. Aspirin, an unspecific
COX inhibitor, was first synthesized and
introduced into clinical practice in the
1890s and has from that time on been
used all over the world for the treatment
of fever, inflammation, and pain. In the
1940s, aspirin was also found to have anti-
thrombotic effects, making it suitable as
protection against myocardial infarction
and blood clots. More recently, hundreds
of clinical studies have demonstrated that
Aspirin and related compounds, such as
Ibuprofen and Diclofenac, so-called non-
steroidal anti-inflammatory drugs (NSAIDs;
Fig. 3), can decrease the incidence of
colorectal, esophagal, lung, and bladder
cancers, thus supporting the hypothesis
that there is a close association between
inflammation and cancer. 
In the last years, pharmaceutical research
has developed a large number of com-
pounds – so-called second-generation
NSAIDs – such as Rofecoxib, Celecoxib, 
or Valdecoxib showing a much higher
affinity and selectivity towards COX-2
than Aspirin. Celecoxib has a selectivity
ratio of COX-2/COX-1 = 375:1; in
contrast, Aspirin inhibits COX-2 and 
COX-1 in the ratio 1:1. Based on the lead
structure of Rofecoxib with the common
structural feature of two aryl rings on
adjacent atoms of a five-cyclic moiety, we
have developed a novel COX-2 inhibitor
radiolabeled with the short-lived positron
emitter C-11 (t1/2 = 20.4 min). This was
realized through a methylation reaction of
the corresponding desmethyl precursor
with [11C]methyl iodide (Fig. 4).
The new radiotracer was fully character-
ized in vitro and in vivo including cell-
uptake studies, metabolism, and
biodistribution studies in normal rats as
well as small-animal PET studies in nude
mice bearing the human colorectal
adenocarcinoma tumor HT-29 (Fig. 5). The
tracer and its non-radioactive counterpart
show a very high affinity for COX-2 as
well as a favorable COX-1/COX-2
selectivity profile (COX-2/COX-1 ratio:
2000). Our results indicate that the novel
tracer compound has the potential as a
COX-2 PET radiotracer, allowing the
quantification of COX-2 expression related
to tumorigenic processes, e.g. in colorectal
cancer. However, the contribution of tumor
cells and proinflammatory cells like macro-
phages to the overall uptake of the tracer
in tumors, tumor environment, and/or
inflammatory lesions still has to be
elucidated further [2].
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Fig. 5: Representative coronal small-animal PET
image showing the tumor uptake of the novel
11C-radiolabeled COX-2 inhibitor in HT-29 tumor
(red circle) bearing mice 50 minutes after single
intravenous application. 
Fig. 4: Synthesis of the novel 11C-radiolabeled COX-2 inhibitor by radiolabeling of the desmethyl












Holger Stephan, Hans-Jürgen Pietzsch
In the middle of the eighties, it was
discovered that certain tumors over-express
receptors for neuropeptides. Since then,
neuropeptides have aroused an increased
interest in cancer research for the in vivo
diagnosis and radiotherapy of tumors over-
expressed by neuropeptide receptors.
Compared to macromolecules, such as
monoclonal antibodies, the use of small
peptides (fewer than 30 amino acids) as
tumor-localizing radiopharmaceuticals is
advantageous due to their low molecular
weights, which empirically improves the
penetration of the tumor tissue. Also, a
faster clearance of healthy tissue is to be
expected and, thereby, an improved
tumor/non-tumor radioactivity ratio.
Peptides usually do not have antigen
characteristics and feature high affinity and
specificity to a number of neuropeptide-
specific receptors. Therefore, the devel-
opment of radiolabeled peptides is an
intensely investigated and fast progressing
field of research. Altogether, this chemical
family offers a promising perspective to
detect tumors and metastases early and
treat them effectively.
The successful clinical application of
radiolabeled somatostatin peptide analogs
(Fig. 1) for imaging receptor expressing
tumors has pressed ahead the modification
of other regulating peptides, such as
neurotensin, RDG peptides, or bombesin,
as possible tumor diagnostics and tumor
therapeutics. On the road to those new
radioactive drugs, quite a number of tricky
issues need to be tackled. This particularly
concerns the development of chemically
and radiolytically stable compounds, which
permit unsophisticated labeling of peptides
with suitable radionuclides.The respectively
labeled compounds are then expected to
transport the activity inside the body
Radiometalated peptides 
for tumor localization and therapy
Fig. 2: Bifunctional chelate agents (BFCAs), which simultaneously allow the stable fixation of radionuclides
and the coupling of suitable peptides (arrows show the positions of BFCAs for the linkage to the peptides;
peptides are mainly coupled via the N-terminus, usually the C-terminus interacts with receptors). 
Fig. 1: DOTATOC - a chelated
somatostatin analog - which can
be labeled stably with either the
positron-emitting 68Ga (imaging)
or beta-emitting radionuclide 
90Y (therapy). The affinity of
DOTATOC for somatostatin
receptors was found to be very
high. High response rate in
patients with tumours of
gastrointestinal tract or lungs
could be demonstrated in clinical
studies [H.R. Mäcke et. al.:
Journal of Medicinal Chemistry
51, 4030 - 4037 (2008)].
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exactly to the targeted tumor without
damaging vital organs, such as the liver 
or kidney. Regarding their application in
diagnostic nuclear medicine, but especially
in therapy, radiometals are particularly
suitable for labeling biomolecules.
Generally, radiometals are fixated stable by
chemical compounds possessing several
complementary trapped atoms for the
metal ion to be bound. In this way, the
radiometal is embraced, just like prey being
grabbed by crawfish pincers. Hence, the
name of the compound family: chelating
agents (Greek: chele = crawfish pincer).
Compounds possessing units for the
complex formation of the metal as well as
for coupling to biomolecules are named as
bifunctional chelate agents (BFCAs). At the
moment, the design, development, and
characterization of such compounds are
intensely pursued at the Institute of Radio-
pharmacy. Fig. 2 shows a number of
promising compounds used for radio-
labeling peptides. 99mTc, 64Cu, and 68Ga-
labeled peptides are basically suitable 
for tumor diagnostics [1-3]. Analog
compounds with the particle-emitting
radionuclides 67Cu and 188Re feature a
great potential for tumor therapy.
Radiolabeled peptides based on bombesin
derivatives represent very interesting
targeting vector molecules for certain
varieties of cancer. Bombesin is an am-
phibious peptide consisting of 14 amino
acids and was first isolated from the skin 
of the frog Bombina orientalis in 1970
(Fig. 3). Several bombesin derivatives 
show very high selectivity and affinity 
to G-protein-coupled gastrine-releasing
peptide receptor (GRPr; Fig. 4). In this 
way, the gastro-intestinal hormone release
is for instance stimulated. Furthermore, 
it is known that bombesin is also involved
in developing breast, lung, pancreatic and
prostate cancer, which is connected with
the enormous over-expression of GRPr.
Therefore, the application of radiolabeled
bombesin-analogs for the diagnostics and
therapy of such tumors is intensely
examined at present.
Pyridine-containing macrocyclic amine
ligands IV and bispidine V, which
simultaneously allow the connection of the
peptide bombesin, have been developed
Fig. 3: Molecular structure of the amphibious tetradecapeptide bombesin (top); electrostatic potential
surface of bombesin (bottom).
Fig. 4: Cartoon of gastrin-releasing
peptide receptor (bombesin receptor
subtype 3 X-ray crystal structure
(Brookhaven protein data bank,
pdb id 2qw4).
Fig. 5: Biodistribution of 64Cu-IVa (see molecule chain above diagram)
in male Wistar rats 5 and 60 min after single intravenous application. 
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for the stable fixation of copper radio-
nuclides (cf. Fig. 2). Thus, the conjugation
of metabolically stabilized bombesin
derivatives to these ligands was success-
fully achieved via amide coupling. These
bioconjugates Ia and IIa can rapidly 
form very stable radiocopper complexes. 
In vitro ligand competition experiments
and stability studies in rat plasma medium 
gave no evidence of transchelation or
demetalation. Biodistribution studies of 
the bombesin conjugate IVa revealed an
accumulation of the compound in the
pancreas, which is the organ with highest
levels of the gastrin-releasing peptide
receptor targeted by bombesin (Fig. 5).
Recently, we have developed a bispidine-
bombesin conjugate Va, whose radio-
copper complex is accumulated by human
prostate tumors (Fig. 6). This allows clear
visualization of the tumor tissue and a
noticeable delimitation from healthy tissue.
Altogether, we developed a number of
new bifunctional chelate agents featuring
very high chemical and radiolytical stability
and allowing a stable bond of diagnostic
(64Cu, 68Ga, 99mTc) and therapeutic 
(67Cu, 188Re) radiometals. At the same
time, coupling of target-oriented peptides
is enabled in a simple way. However, a
number of essential issues are still to be
resolved. This particularly concerns the
metabolic stabilization of applied peptide
molecules, as well as the direct fixation of
radiometalated conjugates in the tumor
tissue. These ambitious aims call for
interdisciplinary cooperation of chemists,
biochemists, biologists, and medical
scientists of our Institute, the University
Hospital Dresden and colleagues from
Heidelberg and Melbourne.
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Fig. 6: Coronal sections of a small-animal PET study of two PC-3 tumor-bearing mice
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Fighting cancer with radioactive microparticles
Eik Schiller1, Hans-Jürgen Pietzsch, 
Ralf Bergmann
Primary liver carcinoma is one of the most
common cancers worldwide and, because
of poor prognosis, the third most common
cause of death from cancer. Additionally,
the liver is often the site of secondary
metastases, especially from colorectal
cancer, the second most frequent
malignancy in developed countries.
Notwithstanding the urgency of the
problem, there is still a lack of effective
treatment for many patients with the
consequence of median survival times of
only a few months. Curative treatment is
limited to liver transplantation or resection.
But only a minority of patients are
candidates for these treatments, owing to
size, number, or location of the lesions.
Tests to kill liver cancer cells by external
ionizing radiation failed because of the
damaging impact on the surrounding
healthy liver tissue. Instead, a novel
approach is to bring ionizing radiation
directly into the tumor to spare normal
liver tissue from radiation damage. This
can be realized by applying radioactively
labeled particles via a catheter into the
artery supplying the tumor with blood. 
The particles spread out in the capillary
bed and – owing to their size – are trapped
at the end of the blood vessels. The
surrounding tumor cells are then killed 
by the radiation of the radionuclides 
which are attached to the particles.
Unfortunately, this method – called
radioembolization – suffers so far from 
the absence of optimal carrier particles. 
Radioactively labeled protein micro-
particles derived from denatured
human serum albumin (HSA micro-
spheres)
In a joint research project of the Institute
of Radiopharmacy and ROTOP Pharmaka
AG, we derivatized protein microparticles
derived from denatured Human Serum
Albumin (HSA microspheres, HSAM) in
such a way that they can be labeled with
therapeutic radionuclides. These particles,
having between 15 and 25 µm in diameter
(Fig. 1), show favorable characteristics in
comparison with particles investigated so
far: they are biocompatible and biodegrade
in the capillary bed of the tumor with time,
which means that repeated therapy after a
couple of weeks is possible. 
The crucial factor in the development of
radiolabeled particles is the absolutely
stable fixation of the therapeutic
radionuclide (beta-emitter) on or in the
particles. Leaching or dissolving the
radionuclide from the particles would lead
to undesirable radiation exposure of
healthy tissue and organs. We derivatized
HSA microspheres with 1,4,7,10-tetra-
azacyclododecane-N,N’,N’’,N’’’-tetraacetic
acid (DOTA), a chelator which forms stable
complexes with the therapeutic radio-
nuclide yttrium-90. A derivative of this
chelator was covalently bound onto the
surface of HSA microspheres as illustrated
in Fig 2. 
In order to investigate the stability of our
modified microspheres, we labeled them
with 86Y. This positron-emitting radio-
nuclide serves as surrogate for the pure
beta emitter 90Y because of its favorable
dosimetric characteristics, and the
possibility to measure the biodistribution
by small animal positron emission
tomography (PET). Additionally, 86Y is
produced with our own cyclotron and,
Fig.1: Scanning electron microscopy photograph of protein microparticles derived from denatured Human
Serum Albumin (HSA microspheres, HSAM). They have been designed in such a way that they can be
labeled with therapeutic radionuclides. These particles, having between 15 and 25 µm in diameter, are
biocompatible and biodegradable.
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therefore, is readily available. In vivo
tests in rats revealed a high stability of 
86Y-labeled HSA microspheres [1]. In these
experiments, the radiolabeled microspheres
were intravenously applied and accumu-
lated within a few minutes exclusively in
the capillary bed of the lung. Conclusions
on the stability of the radiolabeled
microspheres can be drawn from the
disappearance of radioactivity from the
lung over time. In our experiments, no
decay-corrected loss of radioactivity in the
lung was found. Moreover, no radioactivity
accumulation in other organs than the lung
was observed 48 hours after injection of
the 86Y-labeled microspheres (Fig. 3). This
positive result justifies further
investigations.
At present, scientists from the Institute of
Radiopharmacy and ROTOP Pharmaka AG
are translating the results of our basic
investigations on the synthesis of deriva-
tized HSA microspheres into more prac-
tically relevant standards. The ROTOP
Pharmaka AG runs accredited laboratories
for the production of precursors of
radioactive drugs. Here, derivatized HSA
microspheres for clinical trials can be
produced in accordance with good
manufacturing practice (GMP).
Furthermore, the radiolytic stability of
microspheres labeled with the therapeutic
radionuclide 90Y has to be investigated.
Such labeling studies using high radio-
activity (up to 5 GBq) can be performed in
our own facilities at the FZD, where so-
called ‘warm cells’ allow for handling high
amounts of radioactivity.
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Fig. 2: Schematic representation of HSA microspheres modified with 1,4,7,10-tetraazacyclododecane-
N,N’,N’’,N’’’-tetraacetic acid (DOTA), a chelator which forms stable complexes with the therapeutic
radionuclide 90Y. A derivative of this chelator was covalently bound onto the surface of HSA
microspheres and finally labeled with 90Y, resulting in the absolutely stable fixation of the therapeutic











Fig. 3: 86Y-labeled HSA microspheres are intravenously applied in the rat and accumulate within a few
minutes exclusively in the capillary bed of the lung. The figure shows the distribution of radioactive
microspheres 48 hours after injection. It can be seen that no loss of radioactivity from the lung occurs.
Moreover, no radioactivity accumulation in other organs than the lung is observed.
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Klaus Strobel, Jens Pietzsch, 
Jörg van den Hoff
Magnetic resonance imaging (MRI) is an
important non-invasive tomographic
imaging technique firmly established in
clinical routine and research. More
recently, it has been increasingly recog-
nized as a valuable tool for preclinical
research, too, and dedicated machines for
investigation of small laboratory animals
have become available. In contrast to some
other tomographic methods, notably
positron emission tomography (PET) and
X-ray computed tomography (CT), MRI
does not utilize ionizing irradiation in the
imaging process. Instead, magnetic
properties of atomic nuclei are exploited.
Ultimately, the absorption and re-emission
of electromagnetic radiation in the radio-
frequency range provide the imaging
signal. The main advantage of MRI in
comparison to CT imaging is the much
better soft-tissue contrast which, more-
over, can be tailored to specific needs by
choosing distinct acquisition sequences.
More recently, the additional ability to
perform spatially resolved magnetic
resonance spectroscopy (MRS) has become
available. By these means, it is for instance
possible to determine the concentration of
relevant metabolites in metabolic pathways
of interest. By comparing the relative
metabolite concentrations, conclusions
concerning the mechanisms of different
pathologies, e.g. obesity and diabetes
mellitus, can be drawn [1] (Fig. 1). 
Multimodality imaging is a powerful
approach in cancer research that provides
a panoply of anatomical, morphological,
histological, biochemical, and quantitative
functional information. Currently, the
development of highly sensitive and
specific multimodality imaging method-
ologies based on the combination of
different in vivo techniques, notably
MRI/MRS, PET, CT, and (infrared) optical
imaging, as well as ex vivo autoradio-
graphy, is a major challenge in many
experimental cancer centers. By merging
the results from the different methods a
complete overview of the metabolic and
morphologic information can be obtained.
In this context, the realization of multi-
modality imaging of xenotransplanted or
syngene tumor mouse models requires 
the solution of specific problems. Our
group has systematically investigated the
following problems which stand out, and
developed a solution: a) magnetic field
inhomogeneity in the tumor periphery
caused by transition of the magnetic field
from tissue to the surrounding air, which
makes MRS in the tumor periphery 
difficult or impossible, and b) reproducible
positioning for subsequent histological
sectioning of the excised tumor ex vivo.
As an essential prerequisite, we have
developed a novel method for tumor
embedding [2]. Experiments using
phantoms and tumor mouse models were
performed using a 7 Tesla small animal
magnetic resonance tomograph (Fig. 2).
MRS was performed to detect the
magnetic field inhomogeneities. For
phantom embedding, three different
materials were investigated: i) alginate
(Fig. 3), ii) gelatin, and iii) a mixture
(“dough”) of wheat flour, sodium chloride,
and potassium aluminum sulfate dodec-
ahydrate. Alginate is easy to handle and
was thus demonstrated to be superior to
Small animal magnetic resonance imaging 
and spectroscopy for tumor research
Fig. 1: a) Coronal MRI slice through the abdominal region where the intra-abdominal white adipose
tissue (WAT) is located. b) Representative localized in vivo 1H-spectrum (voxel size = 2 mm x 2 mm x 2
mm) of adipose tissue of a mouse. Nine different lipid peaks characteristic of a spectrum of triacylglycerol
are shown. The chemical shift of the peaks is shown in ppm (1 ppm = 300 Hz) of the larmor frequency
(300 MHz) and the intensity of the peaks has arbitrary units.
Fig. 2: Small animal magnetic resonance tomo-
graph with a magnetic field strength of 7 Tesla
(BioSpec 70/30, Bruker BioSpin MRI GmbH,
Ettlingen, Germany).
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gelatin and dough. Gelatin disrupted
during freezing and did not yield an
improvement of the magnetic field
homogeneity. Dough showed an
improvement in the magnetic field
homogeneity, but was not stable during
histological sectioning. On the other hand,
alginate showed an improvement in the
magnetic field homogeneity and,
moreover, histological sectioning after
freezing succeeded very well. Therefore,
for embedding of tumors alginate is
favored. The animals were placed in an
animal bed including position markers
(filled with a mixture of water and
[18F]fluorodeoxyglucose ([18F]FDG)) 
which are visible in MR, PET, and CT
images (Fig. 4). Prior to histological sec-
tioning, the embedded tumors were shock
frozen in liquid nitrogen and then glued
with the flat part of the mold onto the
specimen disc of the microtome (Fig. 5). 
The novel embedding technique using
alginate showed a significant improvement
of the full width at half maximum (FWHM)
of the water peak in the peripheral rim of
the tumor in comparison to the FWHM of
the spectra without embedding (41±10 Hz
vs. 80±20 Hz, p < 0.001). The FWHM in
the center of the tumor is significantly
lower (32±9 Hz vs. 47±20 Hz, p < 0.05).
Image fusion between the MR image and
the PET image ([18F]FDG) was very
successful due to the position markers
(Fig. 4). Image fusion was performed using
the software tools ROVER and FRINE (in-
house development together with the
project partner ABX GmbH). Autoradio-
graphy and histological staining with the
same slice position and direction as the 
MR and PET images are possible due to
the fact that the alginate molding around
the tumor sticks very well on the tumor
after freezing. Our investigation showed
that alginate exhibits the properties
needed for multimodality investigations
with MRS and histological sectioning
simultaneously, namely easy handling,
elimination of magnetic field inhomo-
geneities, and a texture suitable for
histological sectioning. On the basis of
these methodological investigations,
ongoing experiments employ various
target nuclei in MRS like 1H, 13C, 31P, and
19F to characterize tumor processes or
other pathophysiological situations. 
References
[1] Localized proton magnetic resonance 
spectroscopy of lipids in adipose tissue 
at high spatial resolution in mice in vivo, 
K. Strobel, J. van den Hoff, J. Pietzsch, 
Journal of Lipid Research 49, 473 (2008)
[2] A novel embedding technique for multi-
modality imaging of xenotransplanted 
tumor models, K. Strobel, S. Meister, 
R. Bergmann, J. van den Hoff, J. Pietzsch, 
Magnetic Resonance Materials in Physics 
(MAGMA) 21, Suppl. 1, 267 (2008)
Project partners
· Clinic and Policlinic of Nuclear Medicine, 
University Hospital Carl Gustav Carus 
Dresden, Germany
· OncoRay – Center for Radiation Research in 
Oncology, Clinic of Radiotherapy, Faculty of 
Medicine, Technische Universität Dresden, 
Germany
· ABX Advanced Biomedical Compounds 
GmbH, Radeberg, Germany 
Fig. 3: Balloon phantom filled with a water/ethanol
(5%) mixture and embedded in an alginate
molding.
Fig. 5: Picture of the histological sectioning of the
hind leg of a NMRI nu/nu mouse bearing a tumor
xenograft embedded in alginate molding.
Fig. 4: Combined MR/PET imaging and localized MRS using the novel embedding technique. Shown are
coronal images of a tumor xenograft in the hind leg of a nude mouse. The MR image (a) yields superior
morphological information and definition of tumor boundaries. Contrary to the MR image, the PET
image (b) – using the glucose analogue [18F]fluorodeoxyglucose as tracer – shows clear differences
between tumor periphery and its central region due to differences in metabolism. The excellent spatial
coregistration of both images can be appreciated in the fused image (c). The differences visible in the
PET data can further be correlated to differences visible in the localized 1H-MR spectra of tumor rim (d)
and center (e). The chemical shift of the peaks is shown in ppm of the larmor frequency (300 MHz) and
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Intense laser-matter interactions 
for particle and radiation generation
Thomas E. Cowan, Ulrich Schramm, 
Bernd Schmidt
An important new direction at the FZD 
is the generation of intense particle and
radiation sources by ultra-intense laser-
matter and laser-electron interactions,
using the new 150 TW “Draco” laser at
ELBE, commissioned in fall 2008. These
include intense and pulsed, ultra-low
emittance beams of multi-MeV protons
and ions, several hundred MeV to several
GeV beams of low-emittance electrons,
intense characteristic X-ray and brems-
strahlung bursts, and collimated beams 
of tunable X-rays by relativistic Thomson
scattering. In essence, we shall use the
ultra-intense electromagnetic field of the
laser to accelerate electrons in the target
(either a solid, plasma or the ELBE electron
beam itself), in a way analogous to how
the superconducting cavities of the ELBE
shape the radiofrequency power to
produce longitudinal accelerating electric
fields. In comparison, the laser fields are
much stronger and of much higher
frequency than the accelerator RF, and
either solid targets, or plasma filaments will
be used to replace the waveguide structure
to produce longitudinal fields suitable for
proton, ion, and electron acceleration, 
but with extremely high gradient, up to
1012 V/m (about 105 times stronger than 
in ELBE). 
Ultra-intense laser interactions will enable
ultrafast measurements of processes using
simultaneously multiple species of probe
radiations (i.e. with combinations of
electrons, protons, ions, neutrons, X-rays,
gamma-rays, and optical beams) which 
are both extremely intense and of short
duration (fs – ps). This complements and
extends the present capabilities of ELBE,
which produces a single radiation species,
but with high average power desirable for
enabling high counting rate capabilities.
The laser-ion acceleration topic will in
addition provide much of the basis for
advanced tumor therapy research using
laser-driven beams.
During the construction and commission-
ing phases of Draco, an active research
program has been developed, in collabor-
ation with other laser-plasma groups using 
a variety of laser facilities worldwide. This
has aided the preparation of experiments
planned for Draco, by allowing the
preliminary test of new concepts. A
continuation of these collaborations will
also provide access to facilities having laser
parameters which complement those of
the FZD Draco laser. Important efforts
have included: improving the laser
acceleration of protons with new target
geometries; manipulating the accelerated
protons; and developing brighter X-ray
sources through a better understanding of
the laser interaction and energetic electron
dynamics in micro-structured targets. 
Fig. 1: Electron microscope picture of a nanofabricated laser-proton acceleration target made from
10 µm thick gold (left). The high intensity laser is incident from the left into the interior of the cone;
protons are accelerated from a hydrogen layer on the flat disk. The spectrum of accelerated proton
energies (right) exhibits a 4-fold greater flux and higher energy range (blue data) as compared to a
flat foil target (green points). 
Fig. 2: Next generation of reduced mass targets, produced by semiconductor processing techniques
in the Ion Beam Center. Left: Silicon wafer mounting structure (0.5 mm x 0.5 mm open area), with
10 µm x 10 µm target (inset), during fabrication. The triangles are fiducial marks to aid in the laser
beam alignment. Right: completed free-standing 50 µm x 50 µm target. 
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Together with researchers from the US and
Germany, we have collaborated at the
Trident Nd:glass laser facility of Los Alamos
National Laboratory (New Mexico, USA) to
explore novel micro-structured targets as a
means for improving proton acceleration
[1]. In experiments conducted at 30 TW
(20 J per pulse in 600 fs), a 4-fold
enhancement in the total conversion of
laser energy to accelerated protons was
observed, as compared to using con-
ventional flat metallic foil targets, as well
as an increase of the maximum proton
energy (Fig. 1). A second experiment at
200 TW (100 J in 500 fs) is in progress. An
important next step is to understand the
performance of micro-structured targets
with the shorter-duration pulses from
Draco, to determine whether cones, or
other shaped targets, also benefit particle
acceleration in this regime. Also in
collaboration with American and German
partners, we have demonstrated for the
first time the focusing of laser-accelerated
protons with specially designed, high field
permanent magnet quadupole lenses [2].
We have begun a new development at the
FZD together with the High Magnetic Field
Laboratory (HLD), to explore the use of
pulsed high field magnets as a means to
better capture and manipulate the laser-
accelerated protons and ions from Draco.
If successful, this could be beneficial for
future applications, such as compact ion
accelerators for medicine.
Using the 100 TW glass laser (20 J in
300 fs) at the Laboratoire pour l’Utilisation
Lasers Intenses (LULI) in France, and in
collaboration with further partners, we
have explored the use of very small
“reduced mass targets” to enhance the
acceleration of protons. This is predicted 
to arise through the spatial confinement 
of the copious MeV electrons generated 
by the laser, in the strong space charge
electric field produced because of the small
target volume. Preliminary results indicate
an increase in the maximum achieved
proton energy, which could be very
important for medical applications if this
effect persists into the laser parameter
range of Draco. Together with the Ion
Beam Center at the FZD, we are
developing much smaller targets (Fig. 2),
having an area about 100 times smaller
than used in our first experiments. We
shall study these at Draco, as well as with
higher energy lasers, to better understand
the fundamental electron dynamics in
these novel targets, and to explore their
reproducibility and what eventual
improvements can be achieved.
Also at LULI, together with American,
Japanese, and Italian colleagues, we are
studying micro-cone targets for intense 
X-ray generation [3]. In this case, the
conical shape improves the laser ab-
sorption efficiency, and also results in
strong, self-generated magnetic fields (up
to 1000 Tesla) inside of the target material.
These fields trap electrons having energies
up to about 200 keV in the tip region of
the cone target, which is an extremely
bright emitter of characteristic K-shell 
X-rays (Fig. 3), with a simultaneously much
smaller source size than from conventional
X-ray tubes. This could become an
interesting source for diagnostic X-ray
imaging, with high spatial resolution at low
X-ray dose, or to precisely locate the tumor
just prior to the particle beam delivery, in
image-guided radiotherapy. 
These and other collaborative activities (for
example with MPQ on laser acceleration of
electrons [4]) have helped to position the
FZD as a strong partner in the worldwide
community of intense laser-matter inter-
action physics, and to identify important
experiments to be pursued at Draco.
Moreover, our ongoing work on a variety
of laser systems having complementary
pulse characteristics will help to determine
the optimal parameters for next generation
PW-class lasers, which will be developed
for more targeted applications, such as
radiation therapy research and the
development of new radiation sources 
for the research mission of the FZD.
Fig. 3: Nanofabricated cone target (left), for generation of extremely bright copper K· X-rays. The
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RESEARCH INSTITUTE OF RADIATION PHYSICS
Fine Fiedler, Wolfgang Enghardt
In modern cancer treatment radiation
therapy is widely used. Besides state-of-the
art technology based on photon or elec-
tron beams, ions play an increasingly
important role in this field, which can 
be attributed to their favorable physical
properties and clinical results [1, 2]. Due 
to delicate clinical treatment situations, a
specific monitoring procedure, referred to
as in-beam PET (PET is short for positron
emission tomography), has been
developed at the Forschungszentrum
Dresden-Rossendorf (FZD) and successfully
integrated into the therapeutic treatment
unit at the Gesellschaft für Schwerionen-
forschung (GSI) in Darmstadt [3]. 
The expertise of the FZD comprises
detector technology, signal processing,
data acquisition, tomographic recon-
struction and clinical application, all
optimized for in-beam PET [3]. This
technology makes use of annihilation 
γ-rays following the decay of unstable
isotopes which are created via nuclear
reactions between ions of the therapeutic
beam and atoms of the tissue. A sophis-
ticated prediction delivers the expected
activity distribution in the treatment
volume, and allows to evaluate the
treatment by comparing it with the
measured volume. Deviations between 
the prescribed and the actually delivered
dose distributions can be revealed,
quantified, and compensated for in the
course of fractionated treatment. This
unique knowledge on in-beam PET is the
subject of a collaboration with Siemens AG
Health Care, aimed at comprehensive
studies and evaluation of technical
solutions integrating PET monitoring 
into particle radiotherapy (PT-PET) for 
the purpose of quality assurance.
Three different technical solutions have
been studied. (1) In-beam PET is a system
capable of registering the annihilation
events during therapeutic irradiation. This
concept is based on double-head large-
area PET scanners of different arrange-
ments. (2) In-room PET stands for a full-
ring PET scanner mounted in the treatment
site in close vicinity to the facility delivering
the therapy beam. The patient has to be
moved into the scanner, i.e. into imaging
position, directly after irradiation. (3) Off-
line PET relies upon a conventional PET/CT
scanner installed outside the treatment
room, measuring the superimposition of
the activity of all portals delivered in one
fraction. 
These three technical solutions have been
evaluated with regard to image quality,
clinically relevant information deduced
from PT-PET images, technical feasibility,
the efforts of development and installation,
the necessary amount of investment, and
the impact of therapeutic radiation to PET
hardware components. The evaluation is
based on the comprehensive experience of
the FZD in developing the first in-beam
PET facility worldwide at GSI Darmstadt,
its clinical operation as well as the appli-
cation of a wide spectrum of research
methodology, comprising experiments as
well as phantom and patient studies in-
beam and by means of computer
simulations. Additional experience has
been gained by clinical off-line PET studies
at the proton therapy facility at the
Massachusetts General Hospital in Boston.
Combining these research results conclu-
sions on the technical capability, the
efficiency, and the clinical potential have
been derived.
As summerarized in the figure, it has been
found that information on the particle
range can be obtained by in-beam and 
in-room PT-PET. In-beam PT-PET scanners
are able to provide images of highest
achievable counting statistics and,
therefore, the most comprehensive gain 
in clinically relevant information. But also
in-room PT-PET, applied to the patient
after irradiating the first field, allows for
sufficiently precise clinical conclusions on
the treatment. Off-line PET is less
recommendable, not only because of the
low count rate and, thus, the low image
quality, but also due to the superimposition
of activity of the two irradiated fields,
which smears the range of information.
Consequently, relevant clinical information
on quality assurance of the therapy is lost
with off-line PET.
Different solutions for a PT-PET system
have been evaluated at the FZD using
more than 10 years of experience with 
in-beam PET in clinical application. A
comprehensive report covering various
aspects to be expected from future
treatment modalities has been assembled
as basis for an industrial solution [4]. 
Optimized detector configurations for particle-
therapy positron-emission tomography (PT-PET)
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Example of a patient with a chordoma
treated at the Gesellschaft für Schwer-
ionenforschung (GSI) Darmstadt with two-
field irradiation, the prescribed dose dis-
tributions (1st field 0.66 Gy, 2nd field 0.37
Gy upper left figures) are displayed. The
graph shows a count-rate-time histogram
of a real patient measurement, the areas of
the different time spans investigated for a
PT-PET solution are marked. If offline-PET
is applied, the activity originating from 
the second field (green dotted line) also
contributes to the measured signal (blue
dashed line). In the in-beam and in-room
case, the PT-PET measurement is per-
formed for the first field. In case of offline
PT-PET, the measurement is performed
after irradiation of both fields. The middle
row schematically shows the different
scenarios for PT-PET. In the lower row, the
simulated β+-activity distributions for the
different technical solutions are depicted
(isoactivity lines are decoded in rainbow
colors and denote 5, 15, ..., 95 % of the
maxima). For in-beam and in-room PT-
PET, the range information for the ions 
of the therapeutic beam is conserved, for
offline PET, the superimposition of both












Jörg Pawelke, Elke Beyreuther
Radiotherapy is a mainstay of cancer
treatment. With increasing tendency, more
than 50 % of tumor patients in developed
countries receive radiotherapy, either as
the only method of treatment or as a
crucial component in combination with
other modalities such as surgery or
systemic treatment. In order to cure the
patient, all cancer stem cells need to be
inactivated while saving the surrounding
healthy tissue. In many cases, especially for
compact, deep-seated, radiation-resistant
tumors growing in close vicinity to organs
at risk, these objectives cannot be reached
by state-of-the-art radiotherapy
technology, which is based on photon or
electron beams delivered by compact
electron linear accelerators, and applies
modern techniques such as intensity-
modulated and image-guided radio-
therapy. Further considerable progress 
to improve conformance of radiation dose
to tumor volume will derive from the
utilization of ion (i.e. proton and light ion)
beams due to their favorable physical and
radiobiological properties, which have
already been demonstrated in clinical
application. However, there are only few
ion therapy facilities running worldwide
due to their complexity, large scale, and
high investment cost linked to present
radiofrequency accelerator technology.
The German Federal Ministry of Education
and Research (BMBF) have been funding
the onCOOPtics project which focuses on
a rapidly evolving new technology: particle
acceleration based on high-intensity laser
systems. It promises the development 
of ion accelerators of compact size and
reasonable costs, which may be integrated
into existing hospitals. This way, many
more patients could benefit from ion
radiotherapy and its favorable properties.
The onCOOPtics project is jointly carried
out by the OncoRay center for radiation
research in oncology in Dresden with its
partners University Hospital Carl Gustav
Carus Dresden, Technische Universität
Dresden, and Forschungszentrum
Dresden-Rossendorf (see article on page
6), as well as the ultra optics research
center in Jena with its two members
Friedrich-Schiller-Universität and
Fraunhofer Institut für Angewandte Optik
und Feinmechanik. onCOOPtics is an
interdisciplinary research project which
started in April 2007 and combines the
development of high intensity optics and
laser technology, on the one hand, and
research on laser radiooncology, on the
other hand. Both complementary research
topics aim at exploring the yet unexploited
potential of novel laser-particle acceler-
ation technology for high-precision ion
radiotherapy.
Cell response to laser-accelerated electron beams
Fig. 1: Experimental setup at the JeTi laser electron accelerator: The laser pulses are focused into a helium
gas jet, ionizing the gas and generating a plasma wave. Electrons are accelerated and filtered by permanent
magnets and collimators. Behind the filter, a homogeneous electron beam passes through the cell sample
and is detected by several detectors and dosimeters.
Fig. 2: Detection of DNA double strand breaks by immunofluorescence staining 24 hours after irradiation
of mammary epithelial cells (184A1) with a dose of 9 Gy by laser-accelerated electron pulses (left) and
continuous X-ray beams (right), respectively. Each formation of a γH2AX plus 53BP1 foci (colored pink)
indicates a double strand break, whereas DAPI staining of the DNA (colored blue) allows its localization 
in the cell nucleus.
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Particle acceleration requires a very high
laser intensity, which can be obtained by
focusing the light of a high power laser
(terawatt to petawatt) on a micrometer
scale spot size, possible only during ultra-
short (~100 fs) pulses. Accordingly, the
accelerated particle beam pulses are 
also ultra-short, and the resulting high
instantaneous dose rate exceeds that of
conventional medical accelerators by
several orders of magnitude. Before 
their application in radiotherapy, laser-
accelerated ultra-short pulsed beams have
to be explored with respect to their (1)
delivery as therapeutic beams, (2)
detection and dosimetry, and (3)
radiobiological effects on living cells.
Used for basic physical experiments so far,
a laser-accelerator system was customized
for the first cell irradiation experiment of
this kind worldwide (Fig. 1). Pulses of 80 fs
duration of the Jena Titanium:Sapphire 
10 terawatt laser system (JeTi) were
focused into a helium gas jet, accelerating
electrons to energies of up to 20 MeV.
Samples of different living tumor and
normal tissue cells were irradiated with 
a prescribed dose in the range of 0.3 to 
10 Gy on several days over a period of 
10 weeks. Before irradiation, the JeTi
system was optimized for cell experiments
adjusting the beam spot size and im-
proving beam stability as well as dose
homogeneity. An ionization chamber and 
a Faraday cup monitored the electron
beam, providing on-line dose information
necessary for irradiation control. Each cell
sample was equipped with a radiochromic
film used for precise integrated dose
determination, which was demonstrated 
to be accurate even at the very high pulse
dose rate of the laser-electron beam.
Following irradiation, cell mortality was
determined both by the immunochemical
detection of DNA double strand breaks
(Fig. 2), as well as by clonogenic survival
assay. Continuous irradiation with a
conventional X-ray tube (200 kV) was
performed in parallel with reference
experiments at JeTi.
Successful in-vitro cell irradiation by a
laser-driven electron beam presents a first
but very important step on the way to
develop the technology of laser-particle
acceleration for routine radiotherapeutical
application. Several requirements must be
fulfilled relevant for medical application,
such as supply of a stable and reliable
particle beam with reproducible properties
and precise delivery of dose in an appro-
priate irradiation time with required
exposure of a desired irradiation field.
Although not yet fully reaching the
demanding parameters of patient
irradiation, a reasonably stable and
reproducible beam was achieved with 
a dose inhomogeneity within the target 
area of less than 10 % for all days and all
applied doses (Fig. 3). Moreover, the 
dose-effect-curves obtained show that 
the biological effectiveness of the laser-
accelerated ultra-short pulsed electron
beam is generally different compared with
continuous X-ray irradiation (Figs. 2 and 4).
The reason for this is now investigated in
more detail. Experiments are in preparation
at a 100 terawatt laser system, which will
enhance the energy and intensity of the
electron beam, but also provide laser-
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Fig. 3: Correlation of the doses measured online with a Roos ionization
chamber and retrospective with EBT radiochromic films for the irradiation
of 163 cell samples over two months.
Fig. 4: DNA double strand breaks induced in mammary epithelial cells
(normal tissue, 184A1) by short-pulsed laser-electron irradiation (red) and
continuous exposure at a conventional X-ray tube (black).
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4D PET/CT for image guided radiotherapy 
of lung cancer
Wolfgang Enghardt, Charles Gillham1,
Christian Richter
Lung cancer is the most common cancer
worldwide and seems likely to remain 
so for the next future. For patients with
inoperable, loco-regionally advanced 
non-small cell lung cancer (NSCLC) the
prognosis is poor. Since the primary tumor
and lymph node metastases usually lie in
close proximity to critical normal tissue, in
particular the lung, the oesophagus, the
spinal cord, or the heart muscle (Fig. 1), 
the prescribed dose to the tumor has
traditionally been limited to 60 – 70 Gy.
Such tumor dose leads to considerable
local failure of radiation therapy and rather
poor 5-year survival rates. 
The relationship between total radiation
dose and local tumor control as well as
survival rate indicates that a feasible
strategy to improve the therapy outcome 
is the escalation of tumor dose, while the
dose to healthy tissue is held constant or
even decreased. This reflects a well known
fact (Fig. 2) which was already discovered
by the German radiologist Hermann
Holthusen in 1936 [1]. It has been
validated for lung cancer in a number of
clinical trials in several institutions applying
conformal fractionated radiotherapy. To
reduce the radiation dose to sensitive
normal tissue without compromising tumor
coverage, several strategies are feasible: 
(i) For enhancing the reliability of target
volume definition and thus to reduce
safety margins, traditional X-ray com-
puted tomography is combined with 
2-[18F]fluoro-2-deoxy-D-glucose (FDG)
positron emission tomography (FDG
PET/CT) as displayed in Fig. 3. (ii) To reach
a higher dose conformation to the tumor
by compensating for tumor motion due 
to breathing, modern radiation delivery
techniques like gating (Fig. 4) are applied.
Fig. 1: Treatment plan for the irradiation of 
a non-small cell lung cancer (NSCLC) with 
15 MV photons using two beam portals
impinging the patient from frontal and from
the lower right (left in the picture) direction.
The volume is covered by a safety margin, 
to this region a dose of 95 – 107 % of the
prescribed dose is delivered (light green
region), to the light and dark blue regions 
60 – 95 % and 0 – 60 %, respectively, of the
prescribed dose is delivered.
Fig. 3: 4D FDG PET/CT image of a bronchial
carcinoma. Whereas the 4D CT (grey scale)
reflects the anatomy in great detail without
motion blurring, the 4D-PET (hot metal color
scale) shows the glucose uptake, which is
increased in tumor tissue. Combining the
information delivered by PET and CT the
tumor region (i.e. the target volume for
irradiation) can be determined with high
reliability.
Fig. 2: Relationship between dose and tumor control probability (TCP) – red, normal tissue complication
probability (NTCP) – blue and black, and complication free survival probability (CFSP) – turquoise and
yellow. According to Holthusen [1] the complication free survival probability is given by CFSP = TCP
(1 - NTCP). Improvement of tumor conformality by refined irradiation techniques can move the NTCP
towards higher doses (blue → black) and leads to an elevated survival probability (turquoise → yellow).
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(iii) The technique of adaptive targeting is
based on repeated FDG PET/CT imaging
during the 6 to 7 weeks of fractionated
radiotherapy. Thereby, changes in
anatomy, tumor mobility, and volume can
be detected and permit to shrink the
radiation fields individually.
The Center for Radiation Research in
Oncology “OncoRay”, together with the
Departments of Radiotherapy and Nuclear
Medicine of the University Hospital Carl
Gustav Carus in Dresden, operates
diagnostic (PET/CT) and therapeutic
(electron linear accelerators) devices
displayed in Figs. 5 and 6, which facilitate
such novel therapeutic strategies to be
applied in clinical practice. However, at
present the clinical workflow and in
particular the underlying data acquisition
and processing schemes are not offered as
standard solutions by the suppliers of
medical technology. This workflow has to
connect the diagnostic imaging (PET/CT),
the treatment planning system for
calculating the dose distributions in-vivo,
and the control of the therapeutic dose
delivery. It requires the transfer of several
Gigabytes of data per patient between
these devices. Therefore, the Medical
Radiation Physics research group of
OncoRay, in close collaboration with
Siemens Health Care, Concord, USA, and
Erlangen, Germany, is implementing the
whole chain from diagnostic imaging to
tumor conformal, image guided dose
delivery, in particular (i) the 4D PET/CT
imaging of targets influenced by breathing
motion [3], (ii) the precise attenuation
correction and thereby quantification for
PET images of structures influenced by
breathing motion [3], (iii) the tumor-
conformal treatment planning in moving
organs, and (iv) the gated beam delivery.
The first clinical studies [2] utilizing these
techniques aimed at the dose escalation in
lung cancer by adaptive targeting (i.e. the
reduction of radiation field size during
fractionated radiotherapy) have been
performed.
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Fig. 4: Principle of enhancing the tumor dose conformality by means of gated irradiation: The therapy beam is switched on, when the
tumor has reached a predefined position (e.g. the expiration phase for lung tumors) – left, otherwise the beam is switched off – right.
Fig. 6: The medical electron linear accelerator
Oncor Impression (Siemens Health Care) – left –
equipped with gating beam delivery technology
and an in-room X-ray computer tomograph – right
– for image guided adaptive radiotherapy at the
University Hospital Carl Gustav Carus, Dresden.
Fig. 5: The PET/CT scanner Biograph 16 (Siemens
Health Care) equipped with 4D imaging capability















The Forschungszentrum Dresden-Rossendorf (FZD) is a multi-disciplinary research center
for natural sciences and technology. It is the largest institute of the Leibniz Association
and is equally funded by the Federal Republic of Germany and the Federal States, in
particular by the Free State of Saxony. At the FZD, around 330 scientists are engaged in
three different research programs of basic and application-oriented research. Scientists
working in the Advanced Materials Research program investigate the reactions of matter
in strong fields and at small dimensions. Research and development in the Cancer
Research program is focused on the imaging of tumors and the effective radiation
treatment of cancer. How can humankind and the environment be protected from
technical risks? – This question is in the center of research in the Nuclear Safety Research
program of the FZD.
In the following Facts & Figures section data presenting the scientific output in the Cancer
Research program are given as well as information on staff and funding at the FZD.
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Number of applications for a patent filed in each research
program of the FZD in 2007 and 2008. 
Distribution of positions occupied by scientific personnel in the
Cancer Research program of the FZD. Third-party funded
scientists, guest scientists, and postdocs represented by the
corresponding figures are given in units of paid full-time posts.*
staff scientists              third-party funded scientists
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Scientific staff – Cancer research




















































Share of each research program, as well as of the experimental facilities located at the FZD,
of both core and third-party funding during the last two years.



































































2004        2005        2006        2007       2008
Publications – Cancer research
Doctoral students – FZD
International guest scientists – FZD
Growth in number of doctoral students at the FZD from
2004 until 2008.
Number of peer-reviewed articles by scientists from the
FZD’s Cancer Research program.
Distribution of the international guest scientists who
visited the FZD for the purpose of research between 
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